Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC518 phase 2a study in Huntington's disease
NL-OMON60817Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing PTC518 with Placebo (2 arms). Primary endpoints: Safety profile and Change from baseline in blood total huntingtin protein. Started Sep 2022; status: completed.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON60817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60817.